ASPSCR1: Difference between revisions
Jump to navigation
Jump to search
added Category:Oncogenes using HotCat |
imported>OAbot m Open access bot: add pmc identifier to citation with #oabot. |
||
| Line 5: | Line 5: | ||
{{PBB_Summary | {{PBB_Summary | ||
| section_title = | | section_title = | ||
| summary_text = This gene is a candidate gene for [[alveolar soft part sarcoma]] (ASPS). It has been found that ASPSCR1 can undergo oncogenic rearrangement with transcription factor [[TFE3]] gene, creating an aberrant gene that is a stronger transcriptional [[activator (genetics)|activator]] than TFE3 alone.<ref>{{cite journal | vauthors = Kobos R, Nagai M, Tsuda M, Merl MY, Saito T, Laé M, Mo Q, Olshen A, Lianoglou S, Leslie C, Ostrovnaya I, Antczak C, Djaballah H, Ladanyi M | title = Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein | journal = The Journal of Pathology |date=Jan 2013 | doi = 10.1002/path.4158 }}</ref> This fusion oncogene encodes for a chimeric [[transcription factor]], which is responsible for the production of multiple molecules that contribute to ASPS and also to [[renal cell carcinoma]]s.<ref>{{cite journal | vauthors = Lazar AJ, Lahat G, Myers SE, Smith KD, Changye Z, Wei-Lien W, Lopez-Terrada D, Lev D | title = Validation of potential therapeutic targets in alveolar soft part sarcoma: an immunohistochemical study utilizing tissue microarray | journal = Histopathology | volume = 55 | issue = 6 | pages = 750–755 |date=Dec 2009 | doi = 10.1111/j.1365-2559.2009.03436.x }}</ref> Several alternatively spliced transcript variants of this gene have been described, but their full length nature has not been determined.<ref name="entrez" /> | | summary_text = This gene is a candidate gene for [[alveolar soft part sarcoma]] (ASPS). It has been found that ASPSCR1 can undergo oncogenic rearrangement with transcription factor [[TFE3]] gene, creating an aberrant gene that is a stronger transcriptional [[activator (genetics)|activator]] than TFE3 alone.<ref>{{cite journal | vauthors = Kobos R, Nagai M, Tsuda M, Merl MY, Saito T, Laé M, Mo Q, Olshen A, Lianoglou S, Leslie C, Ostrovnaya I, Antczak C, Djaballah H, Ladanyi M | title = Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein | journal = The Journal of Pathology |date=Jan 2013 | doi = 10.1002/path.4158 | pmc = 4083568 }}</ref> This fusion oncogene encodes for a chimeric [[transcription factor]], which is responsible for the production of multiple molecules that contribute to ASPS and also to [[renal cell carcinoma]]s.<ref>{{cite journal | vauthors = Lazar AJ, Lahat G, Myers SE, Smith KD, Changye Z, Wei-Lien W, Lopez-Terrada D, Lev D | title = Validation of potential therapeutic targets in alveolar soft part sarcoma: an immunohistochemical study utilizing tissue microarray | journal = Histopathology | volume = 55 | issue = 6 | pages = 750–755 |date=Dec 2009 | doi = 10.1111/j.1365-2559.2009.03436.x }}</ref> Several alternatively spliced transcript variants of this gene have been described, but their full length nature has not been determined.<ref name="entrez" /> | ||
}} | }} | ||
Latest revision as of 18:12, 15 May 2018
| VALUE_ERROR (nil) | |||||||
|---|---|---|---|---|---|---|---|
| Identifiers | |||||||
| Aliases | |||||||
| External IDs | GeneCards: [1] | ||||||
| Orthologs | |||||||
| Species | Human | Mouse | |||||
| Entrez |
|
| |||||
| Ensembl |
|
| |||||
| UniProt |
|
| |||||
| RefSeq (mRNA) |
|
| |||||
| RefSeq (protein) |
|
| |||||
| Location (UCSC) | n/a | n/a | |||||
| PubMed search | n/a | n/a | |||||
| Wikidata | |||||||
| |||||||
Tether containing UBX domain for GLUT4 (TUG) is a protein that in humans is encoded by the ASPSCR1 gene.[1][2][3]
This gene is a candidate gene for alveolar soft part sarcoma (ASPS). It has been found that ASPSCR1 can undergo oncogenic rearrangement with transcription factor TFE3 gene, creating an aberrant gene that is a stronger transcriptional activator than TFE3 alone.[4] This fusion oncogene encodes for a chimeric transcription factor, which is responsible for the production of multiple molecules that contribute to ASPS and also to renal cell carcinomas.[5] Several alternatively spliced transcript variants of this gene have been described, but their full length nature has not been determined.[3]
References
- ↑ Ladanyi M, Lui MY, Antonescu CR, Krause-Boehm A, Meindl A, Argani P, Healey JH, Ueda T, Yoshikawa H, Meloni-Ehrig A, Sorensen PH, Mertens F, Mandahl N, van den Berghe H, Sciot R, Dal Cin P, Bridge J (Mar 2001). "The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25". Oncogene. 20 (1): 48–57. doi:10.1038/sj.onc.1204074. PMID 11244503.
- ↑ Joyama S, Ueda T, Shimizu K, Kudawara I, Mano M, Funai H, Takemura K, Yoshikawa H (Oct 1999). "Chromosome rearrangement at 17q25 and xp11.2 in alveolar soft-part sarcoma: A case report and review of the literature". Cancer. 86 (7): 1246–50. doi:10.1002/(SICI)1097-0142(19991001)86:7<1246::AID-CNCR20>3.0.CO;2-4. PMID 10506710.
- ↑ 3.0 3.1 "Entrez Gene: ASPSCR1 alveolar soft part sarcoma chromosome region, candidate 1".
- ↑ Kobos R, Nagai M, Tsuda M, Merl MY, Saito T, Laé M, Mo Q, Olshen A, Lianoglou S, Leslie C, Ostrovnaya I, Antczak C, Djaballah H, Ladanyi M (Jan 2013). "Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein". The Journal of Pathology. doi:10.1002/path.4158. PMC 4083568.
- ↑ Lazar AJ, Lahat G, Myers SE, Smith KD, Changye Z, Wei-Lien W, Lopez-Terrada D, Lev D (Dec 2009). "Validation of potential therapeutic targets in alveolar soft part sarcoma: an immunohistochemical study utilizing tissue microarray". Histopathology. 55 (6): 750–755. doi:10.1111/j.1365-2559.2009.03436.x.
External links
- Human ASPSCR1 genome location and ASPSCR1 gene details page in the UCSC Genome Browser.
Further reading
- Heimann P, El Housni H, Ogur G, et al. (2001). "Fusion of a novel gene, RCC17, to the TFE3 gene in t(X;17)(p11.2;q25.3)-bearing papillary renal cell carcinomas". Cancer Res. 61 (10): 4130–5. PMID 11358836.
- Argani P, Antonescu CR, Illei PB, et al. (2001). "Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents". Am. J. Pathol. 159 (1): 179–92. doi:10.1016/S0002-9440(10)61684-7. PMC 1850400. PMID 11438465.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
- Bogan JS, Hendon N, McKee AE, et al. (2003). "Functional cloning of TUG as a regulator of GLUT4 glucose transporter trafficking". Nature. 425 (6959): 727–33. doi:10.1038/nature01989. PMID 14562105.
- Ota T, Suzuki Y, Nishikawa T, et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs". Nat. Genet. 36 (1): 40–5. doi:10.1038/ng1285. PMID 14702039.
- Gerhard DS, Wagner L, Feingold EA, et al. (2004). "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)". Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC 528928. PMID 15489334.
- Olsen JV, Blagoev B, Gnad F, et al. (2006). "Global, in vivo, and site-specific phosphorylation dynamics in signaling networks". Cell. 127 (3): 635–48. doi:10.1016/j.cell.2006.09.026. PMID 17081983.
 | This protein-related article is a stub. You can help Wikipedia by expanding it. |